Session: SAT 358-380-Steroid Hormone Biosynthesis & Metabolism
Poster Board SAT-361
We analyzed mRNA expression levels of 11βHSD type 2, 11βHSD type 1, H6PD and C/EBPα in hepatocellular carcinoma (HCC) and non-cancerous liver tissue (N) derived from 15 patients with HCC, using real-time RT-PCR with normalization for GAPDH expression. Further, we evaluated their association with clinical parameters.
11βHSD type 2 was detected only in 2 (0.0002 and 0.0059) out of 15 N. However, 11βHSD type 2 expression was confirmed in 14 cases out of 15 HCC with mRNA levels of 0.054 ± 0.008 (mean ± SE). Although the expression level in HCC was about a few tenths of those seen in renal tissues that should have abundant expression, the ectopic expression in HCC has been confirmed. 11βHSD type 1 mRNA levels were 3.06 ± 0.58 in HCC vs. 2.97 ± 0.71 in N, with no significant difference. In contrast, H6PD expression in HCC (2.08 ± 0.71) was significantly higher than in N (0.61 ± 0.18), and C/EBPα expression in HCC (0.163 ± 0.04) was also higher than in N (0.06 ± 0.02). Regarding the clinical data, the expression of 11βHSD type 1 in non-cancerous part was negatively correlated with ICG retention rate at 15 minutes, the indicator of hepatic functional reserve. In addition, negative correlations were found between the 11βHSD type 2 expression level in HCC and the number of platelets or white blood cells.
Thus, cortisol inactivation by 11βHSD type 2 is enhanced in the cytoplasm of HCC cells, which might be associated with the severity of hypersplenism. While increased expression of H6PD and C/EBPα was seen in the cancer portion, the 11βHSD type 1 expression did not differ. However, the expression level of 11βHSD type 1 in the non-cancer portion might be associated with functional hepatic reserve.
Nothing to Disclose: TM, TS, SO, MS, SK, MH, JT, KY, KK
*Please take note of The Endocrine Society's News Embargo Policy at http://www.endo-society.org/endo2013/media.cfm
See more of: Abstracts - Orals, Featured Poster Presentations, and Posters